IFN-Gamma Signaling in Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 78

Special Issue Editor

E-Mail Website
Guest Editor
Department of Biological Sciences, St. John's University, New York, NY, USA
Interests: cancer immunology; transcriptional regulation; cytokines; PD-L1; NFkB
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are thrilled to announce a Special Issue titled "IFNγ Signaling in Cancer". This Special Issue focuses on the intricate signaling pathways and molecular mechanisms through which IFNγ influences cancer development and progression. Since early studies revealed IFNγ’s strong anti-tumor effects, which include its activation of immune cells, cell cycle arrest, and increased cancer cell apoptosis, IFNγ has been used in cancer treatment. In addition, IFNγ expression is induced by radiation and immune checkpoint blockades used in anti-cancer therapies. However, mounting evidence indicates that IFNγ also has important tumor promoting functions that include its ability to induce expression of the immune checkpoint ligand PD-L1 and T cell exhaustion, cancer cell proliferation, and tumor growth.

This Special Issue aims to explore the multifaceted effects of IFNγ on cancer biology. It encompasses understanding how IFNγ influences tumor cell growth and survival, immune cell activation and function, PD-L1 expression and immune escape, and the intricate crosstalk between tumor cells and the tumor microenvironment. A better understanding of the mechanisms and biological significance of the anti-tumor and tumor-promoting IFNγ signaling in cancer cells will lead to the development of novel strategies aimed at increasing IFNγ’s effectiveness in cancer treatment and in anti-cancer therapies associated with increased IFNγ expression, such as radiation and immune checkpoint blockades.

We invite researchers, academicians, and practitioners to contribute original research articles, reviews, and communications that advance our understanding of the role of IFNγ signaling in cancer.

Prof. Dr. Ivana Vancurova
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • IFN-gamma signaling
  • tumor immunology
  • immunotherapy
  • immune checkpoint blockade
  • immune evasion
  • PD-L1
  • tumor microenvironment

Published Papers

This special issue is now open for submission.
Back to TopTop